Shandong Shengli Bioengineering Co., Ltd (Abbreviation: Shengli Bioengineering) is a joint venture company built by China Animal Husbandry Industry Company Limited and Shandong Shengli Company Limited. And it was originally built in 2004 with an total investment of RMB 5 hundred million, and it is guided by bio-fermentation technology, producing animal-specific antibiotic API, veterinary preparations and feed additives, in the meanwhile, it is national high tech enterprise, and regarded as top 10 in national veterinary drug industry and top 10 veterinary drug enterprise in Shandong province.
Shengli Bioengineering is located in national high tech zone, Jining city, Shandong province. And it has covered an area of 70 acre, and equipped with first class facility as well as advanced management. Currently we are primarily manufacturing feed additives, such as Enramycin, Bambermycin, Hainanmycin, Nosiheptide, Monensin and Salinomycin, also veterinary drugs as Tiamulin Fumarate, Florfenicol, Tilmicosin, Doxycycline Hydrochloride, etc. And we are global leader on Tiamulin Fumarate and Bambermycin production and sales, and we are the only manufacturer in the globe that have China self-owned intellectual property on Hainanmycin.
Shengli bioengineering possesses full complete preparations workshop and production line that passes GMP certification, and there are production equipment of first class and high mechanization that manufacture various animal-specific preparations. In strict accordance with current GMP standard in EU and USA, we have been establishing and improving quality control system, and our product have been registered and authenticated in dozens of countries and areas overseas. Among all products, Tiamulin Fumarate API has achieved EU COS certificate in the lead, also have submitted to USA FDA; 80% Tiamulin Fumarate Premix have required Japan FMA certificate; Premix of Tiamulin Fumarate and that of Bambermycin, Monensin, Salinomycin have achieved Australia APVMA certificate. And we are the only self-owned intellectual property patent enterprise in China concerning Enramycin and Avilamycin.
Shengli bioengineering value research and re-innovation on technology import, and set up CAHIC-Shengli bioengineering research institute, and we positively establish cooperation with counterparts and professionals at home and abroad, and many national patent and scientific achievements of us have filled blank in domestic history.
Shengli bioengineering always adhere to the management principle of “Success on quality, Sharing on profit, and all win on prosperity ”, and hope to establish new type of friendly relations and mutual development cooperation with clients. We insist on contract-honoring and promise-keeping, with high brand reputation, we have built marketing net domestically and overseas